SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Nature Medicine"
DOI: 10.1038/nm.4497
Abstract: Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approximately half harbor resistance mutations… read more here.
Keywords: alk inhibitors; alk; rearranged non; inhibition ... See more keywords
Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset
Sign Up to like & getrecommendations! Published in 2017 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx045
Abstract: Introduction Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset… read more here.
Keywords: lymphoma kinase; rearranged non; kinase; anaplastic lymphoma ... See more keywords